Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Oncolytics Biotech received Fast Track designation from the FDA for pelareorep in combination with a checkpoint inhibitor for second-line anal cancer. The designation is supported by GOBLET study data showing a 30% objective response rate and a 12-month overall survival rate of 82%, both significantly exceeding historical rates of 9.5 months duration and 45.7% survival.
Key figures
- Drug Name
- pelareorep
- Dor months
- 15.5
- Orr percent
- 30
- Os 12m percent
- 82
- Market size usd
- $1 billion
- Historical dor months
- 9.5
- Historical os 12m percent
- 45.7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.